According to the research report titled ‘Asia-Pacific In-Vitro Fertilization Market Analysis, 2020’, available with Market Study Report, Asia-Pacific in-vitro fertilization market is expected to grow with a CAGR of 11.35% between the period of 2020 and 2025.
 

Increasing number of fertility clinics coupled with mounting cases of surrogacy among women are some of the key factors driving the growth of Asia-Pacific in-vitro fertilization market. Increased pervasiveness of PCOS (polycystic ovarian syndrome) and improving assisted reproductive technology are also adding traction to the overall market size.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2767205/
 

In terms of cycle type, the market is bifurcated into donor egg IVF cycles, thawed IVF cycles, and fresh IVF cycles. The report states that fresh IVF cycles segment is expected to account for around three-fifth of the total market share in the upcoming years. It is to be noted that fresh embryo IVF cycles starts with the ovarian stimulation and is followed by recovering all eggs from the patient. While some of these eggs are used for developing an embryo, the remaining are stored in frozen IVF cycles.
 

By procedure, Asia-Pacific in-vitro fertilization industry is segmented into frozen embryo transfer/replacement (FET/FER), pre impantation genetic diagnosis (PGD), intra cytoplasmic sperm injection (ICSI) and others.
 

Citing the end-user spectrum, the overall industry is fragmented into cryobanks, clinical research institutes, surgical centers, hospitals, and fertility clinics. Among these, the report cites that fertility clinics and hospitals collectively accounted for 80% of revenue share in Asia-Pacific in-vitro fertilization industry in the year 2019. Availability of advanced treatment options with exceptionally skilled workforce coupled with rising number of fertility clinics are favoring the market outlook in Asia-Pacific.
 

 The product landscape of Asia-Pacific in-vitro fertilization industry consists of devices, reagents, pharmaceuticals, and services segments. The devices segment is further split into consumables, storage and maintenance systems, sample handling systems, gamete collection and sorting systems and other IVF equipment. The reagents segment is also divided into gamete processing media, cryopreservation media, embryo culture media, and others.
 

Vitrolife AB, Olympus Corporation, Thermo Fisher Scientific Inc., The Merck Group, IVFtech ApS, Ferring Pharmaceuticals, FUJIFILM Irvine Scientific Inc., Esco Group, Cook Medical Incorporated, and Adorefem Gynec Pro-Infertility Division are the key participants in Asia-Pacific in-vitro fertilization industry.